Participated · Equity · Jul 2026

Stark Power focuses on developing energy infrastructure and hyperscale data center campuses in the U.S., pursuing a “Power First” strategy that couples co-located power generation with digital infrastructure. The company recently acquired Sagebrush Infrastructure Partners, which is advancing a portfolio of five hyperscale data center campuses in the U.S. Midwest totaling approximately 5.6 GW. Stark Power plans to use proceeds from its latest equity raise primarily to fund complementary power generation assets across its data center portfolio. The firm is backed by institutional investors and increased institutional conviction with Migdal Insurance becoming a significant shareholder through the current financing. The company is headquartered in Tel Aviv and is accelerating development across its pipeline following the Sagebrush acquisition.

Participated · Series F · May 2026

Tomorrow.io positions itself as the world's leading Resilience Platform, combining a proprietary satellite constellation with a generative AI–integrated forecasting engine to deliver weather intelligence. The company says it operates a fully operational proprietary satellite constellation and leverages next-generation space technology, advanced AI, and proprietary weather modeling. Tomorrow.io is deploying DeepSky, described as the world's first AI-native weather satellite constellation, and aims to expand its space-based observation network. Its platform is used to provide real-time, actionable resilience intelligence and is trusted by six of the top ten Fortune 500 companies. The company has been recognized as a TIME 100 Most Influential Company and a Fast Company Most Innovative Company. The recent expansion of its Series F to $210 million is intended to accelerate its AI capabilities and further develop its agentic platform.

Participated · Series A · Dec 2025

Quantum Art was spun out of Prof. Roee Ozeri's group at the Weizmann Institute of Science and is led by CEO and co-founder Dr. Tal David, CTO Dr. Amit Ben Kish and CSO Prof. Roee Ozeri. The company focuses on trapped-ion quantum computing and has developed proprietary techniques for multi-qubit gates, scalable modular architectures, and robust quantum error correction. It is advancing a multi-core roadmap including Perspective, a planned 1,000-qubit system aimed at commercial-scale deployment. Quantum Art is transitioning toward commercialization with plans for a Quantum-as-a-Service (QaaS) platform that lets customers move from algorithm development and co-design to execution on its hardware. The company said it is expanding internationally and building partnerships to support early customer adoption while hiring to support development and business growth.

Led · Series C · Oct 2025

Founded in 2015, Omnix Medical is focused on discovering and developing novel antimicrobial peptide (AMP) therapies that address life-threatening, antibiotic-resistant infections. Its lead candidate, OMN6, rapidly destroys bacterial cell membranes and has received Fast-Track and Qualified Infectious Disease Product designations from the U.S. FDA. The company is currently running Phase II proof-of-concept trials targeting Gram-negative pathogens such as Acinetobacter baumannii, a major cause of hospital-acquired infections. Proceeds from recent funding will also support regulatory preparations, manufacturing scale-up, and advancement of additional AMP candidates in the pipeline. Unlike traditional antibiotics that target specific bacterial functions, OMN6’s pore-forming mechanism minimizes the chance of resistance development. Since inception, Omnix Medical has raised a total of $43 million to finance its R&D and clinical programs.

Led · Seed · May 2024

AISAP offers a POCAD™ solution that applies deep-learning AI to medical ultrasound, delivering automated diagnoses and specialized analyses such as valve-level cardiovascular assessments. The product provides an urgency score to help providers prioritize cases and a scan-quality score to ensure accuracy for operators less familiar with traditional ultrasound devices. Its deep-learning models are designed to yield accurate readings even from lower-quality images produced by handheld machines. The company reports its algorithms were trained on more than 300,000 studies comprising over 24 million video clips, and the technology has been validated by medical experts at The Mayo Clinic, Inova Health Foundation, Jefferson Health, Poriya Institute and others. AISAP plans to use the new funding to expand operations and accelerate development efforts. Leadership includes CEO Roni Attali and cofounders Adiel Am-Shalom, Ehud Raanani, Robert Klempfner and Ehud Schwammenthal.